This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Allogeneic and Autologous Cell Therapies Report 2022

Share this article

In December 2021, Informa Connect and Catalent conducted a worldwide survey of cell therapy professionals to understand the emerging trends in both the allogeneic and autologous cell therapy space. Respondents were asked about their focus areas, product types and phases of their programs, in addition to their decision-making and the most significant challenges to their manufacturing goals.

The full report reveals cell therapy manufacturing trends amid the rapid progression of cell therapy technologies.

Key findings include:

  • 63% of cell therapy professionals are working on both autologous and allogeneic products
  • Supply chain bottlenecks are the most common hurdle that cell therapy professionals have experienced with their programs
  • Respondents gave valuable insights into next-generation innovative technologies they are most likely to adopt

Read or download the report here or by clicking on the image below.

Share this article

Upcoming event

Cell & Gene Therapy Manufacturing & Commercialization Asia

11 - 14 Apr 2022, Presented in Japan Standard Time (JST)
The ONLY Cell and Gene Therapy event in Asia to help you fast track manufacturing & commercialization across borders
Go to site